The Role of Breast MRI in Detecting Asymptomatic Recurrence After Therapeutic Mastectomy

OBJECTIVE. MRI is not routinely used to screen for cancer recurrence after therapeutic mastectomy; however, data on this topic are sparse. We performed this study to determine the utility of breast MRI in detecting asymptomatic locoregional recurrence after therapeutic mastectomy. MATERIALS AND METHODS. A retrospective record review identified all breast MRI studies performed in women who had undergone unilateral therapeutic mastectomy over a 6-year period (January 1, 2010, to January 1, 2016). A total of 402 studies were performed in 191 women between the ages of 26 and 78 years old, none of whom were experiencing symptoms on the mastectomy side. BI-RADS assessments for the mastectomy side were extracted from the radiology reports, and the electronic medical records were reviewed for surgical and oncologic history, clinical and imaging follow-up, and pathologic results. Malignancy was determined by pathologic results. Benignity was confirmed by at least one of the following: pathologic results, at least 12 months of documented disease-free clinical follow-up, or at least 12 months of documented disease-free imaging follow-up. Descriptive statistical and 2 × 2 contingency table analyses were performed. RESULTS. In all, 395 MR images (98.3%) were assessed as showing benign findings on the mastectomy side. Seven (1.7%) were interpreted as showing positive findings on the mastectomy side (BI-RADS category 4, suspicious for malignancy). Biopsy was performed in four of the seven positive interpretations. All four biopsies yielded malignancy for a positive predictive value of biopsy of 100%. The three remaining positive cases did not include biopsy; however, in each case, follow-up imaging showed improvement or resolution of the finding, yielding a positive predictive value of an abnormal examination of 57.1%. Two MRI studies were false-negative, with local recurrence within 12 months after MRI deemed to show benign findings, yielding a negative predictive value of 99.5%. Sensitivity and specificity were 66.7% and 99.2%, respectively. The cancer detection rate in the asymptomatic mastectomy side for all MRI examinations was 10 cancers per 1000 examinations. CONCLUSION. Our findings support inclusion of the mastectomy side in MRI examinations of the contralateral breast to screen for cancer recurrence after therapeutic mastectomy.